A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy
- Akemi Kosaka,
- Yuki Yajima,
- Mayumi Hatayama,
- Katsuya Ikuta,
- Takaaki Sasaki,
- Noriko Hirai
- Asahikawa Medical University,
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Recent studies have revealed that tumor cells decrease their immunogenicity by epigenetically repressing the expression of highly immunogenic antigens to survive in immunocompetent hosts. We hypothesized that these epigenetically hidden “stealth” antigens should be favorable targets for cancer immunotherapy due to their high immunogenicity. To identify these stealth antigens, we treated human lung cell line A549 with DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (5Aza) and its prodrug guadecitabine for 3 d in vitro and screened it using cDNA microarray analysis. We found that the gene encoding sperm equatorial segment protein 1 (SPESP1) was re-expressed in cell lines including solid tumors and leukemias treated with 5Aza, although SPESP1 was not detected in untreated tumor cell lines. Using normal human tissue cDNA panels, we demonstrated that SPESP1 was not detected in normal human tissue except for testis and placenta. Moreover, we found using immunohistochemistry SPESP1 re-expression in xenografts in BALB/c-nu/nu mice that received 5Aza treatment. To assess the antigenicity of SPESP1, we stimulated human CD4<sup>+</sup> T-cells with a SPESP1-derived peptide designed using a computer algorithm. After repetitive stimulation, SPESP1-specific helper T-cells were obtained; these cells produced interferon-γ against HLA-matched tumor cell lines treated with 5Aza. We also detected SPESP1 expression in freshly collected tumor cells derived from patients with acute myeloid leukemia or lung cancer. In conclusion, SPESP1 can be classified as a stealth antigen, a molecule encoded by a gene that is epigenetically silenced in tumor cells but serves as a highly immunogenic antigen suitable for cancer immunotherapy.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 2705-2713 (9 pages)Journal (Volume, Issue Number)
Cancer Science (Volume 112, Issue 7)Publication milestones
- Accepted/In press - 2021
- Published - 07/2021
Publication status
Published - 07/2021
ISSN
1347-9032Publication IDs
- Scopus: 85107026098
- PubMed: 34009705
Publication metrics
Metrics
SciVal
Author count
23
SciVal
Paper percentile
80
Fractional count
1
Fractional count
0.04
Fractional count
22
Fractional count
0.96
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
9
Captures
9
Funding Details
Japan Society for the Promotion of Science (H Kobayashi 16K15244, and T Ohkuri 20K07367) and Japan Agency for Medical Research and Development AMED (A Kosaka JP16lm0103005). This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (H Kobayashi 16K15244 and T Ohkuri 20K07367) and Japan Agency for Medical Research and Development (AMED) (A Kosaka JP16lm0103005). The authors thank Mr. Hayakawa Toshiyuki and Ms. Hino Chihiro (at the Animal Laboratory for Medical Research, Center for Advanced Research and Education, Asahikawa Medical University) and Ms. Matsumoto Rie (at the Department of Pathology, Asahikawa Medical University) for devotedly maintaining the mice.
This study was funded, in part, by Otsuka Pharmaceutical Co., Ltd.
This work was supported by Grants‐in‐Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (H Kobayashi 16K15244 and T Ohkuri 20K07367) and Japan Agency for Medical Research and Development (AMED) (A Kosaka JP16lm0103005). The authors thank Mr. Hayakawa Toshiyuki and Ms. Hino Chihiro (at the Animal Laboratory for Medical Research, Center for Advanced Research and Education, Asahikawa Medical University) and Ms. Matsumoto Rie (at the Department of Pathology, Asahikawa Medical University) for devotedly maintaining the mice.
FundersFunding numbers
AMU
-OPC
-MEXT
-JSPS
18K15300, 16K15244, 20K07367
AMED
JP16lm0103005
